It is not a great mystery that primary ovarian cancer, when presenting with metastatic intra-abdominal and/or extra-abdominal disease, represents a formidable therapeutic challenge, as these women are usually highly symptomatic, frequently of poor nutrition, and in need of aggressive dual modality therapy: surgery and chemotherapy.